CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (Nasdaq: MDGL) granted equity inducement awards to five newly hired non-executive employees on February 15, 2026, the company announced.
The awards were approved by Madrigal’s independent Compensation Committee under the company’s 2025 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
In total, the employees received 2,749 time-based restricted stock units as an inducement to accept employment with the company.
The restricted stock units will vest in four equal installments on each of the first through fourth anniversaries of the grant date, subject to the employees’ continued employment on each vesting date, according to the announcement.
Madrigal is a biopharmaceutical company focused on treatments for metabolic dysfunction-associated steatohepatitis, or MASH.
Its lead product, Rezdiffra (resmetirom), is a once-daily oral therapy approved by the U.S. Food and Drug Administration and the European Commission for the treatment of MASH with moderate to advanced fibrosis, stages F2 to F3.
The company said an ongoing Phase 3 outcomes trial is evaluating Rezdiffra for compensated MASH cirrhosis, or F4c.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.